We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How has the anemia drugs grown historically, and what trends indicate future expansion?
The anemia drugs market size has grown strongly in recent years. It will grow from $14.72 billion in 2024 to $15.92 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to increasing prevalence of chronic diseases, rising awareness of iron deficiency anemia, rise in geriatric population, increasing healthcare access in developing regions, and rising demand for targeted therapies.
The anemia drugs market size is expected to see strong growth in the next few years. It will grow to $21.53 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing adoption of personalized medicine, rising healthcare expenditure in emerging markets, growing number of clinical trials in anemia treatment, rise in global prevalence of anemia, and increasing focus on patient-centric drug development. Major trends in the forecast period include advancement in gene therapy for anemia, advanced delivery systems for iron supplements, innovation in erythropoiesis-stimulating agents, advanced diagnostic tools for anemia detection, and innovation in oral anemia treatments.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24141&type=smp
Which key factors are driving the expansion of the anemia drugs industry?
The increasing focus on personalized medicine is expected to propel the growth of the anemia drugs market going forward. Personalized medicine is a medical approach that tailors treatment and healthcare decisions to an individual’s genetic makeup, lifestyle, and environment. The rising focus on personalized medicine is due to advancements in genomic sequencing, which allow for more precise identification of individual genetic variations linked to disease and treatment response. Personalized medicine supports anemia drug production by enabling tailored treatments based on individual genetic profiles, improving drug efficacy, and minimizing adverse effects for better patient outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for patients with rare diseases, a significant increase from 6 in 2022. Therefore, the increasing focus on personalized medicine drives the growth of the anemia drugs market.
How is the anemia drugs market segmented by product, application, and end-user?
The anemia drugs market covered in this report is segmented –
1) By Drug Type: Dietary Supplements, Medicines
2) By Therapy Type: Oral Iron Therapy, Red Blood Cell Transfusion, Parental Iron Therapy, Other Therapy Types
3) By Anemia Type: Iron Deficiency Anemia, Sickle Cell Anemia, Aplastic Anemia, Hemolytic Anemia, Pernicious Anemia, Others Anemia Type
4) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy
5) By End-User: Clinic, Healthcare, Home Healthcare
Subsegments:
1) By Dietary Supplements: Iron Supplements, Vitamin B12 Supplements, Folic Acid Supplements, Multivitamin And Mineral Supplements
2) By Medicines: Erythropoiesis-Stimulating Agents (ESAs), Iron Chelating Agents, Corticosteroids, Immunosuppressants, Luspatercept And Related Agents
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/anemia-drugs-global-market-report
Which major trends are influencing the growth of the anemia drugs industry?
Major companies operating in the anemia drugs market are focusing on innovative drug developments, such as oral HIF-PHI (hypoxia-inducible factor prolyl hydroxylase inhibitors), to improve iron metabolism and enhance red blood cell production for more effective anemia treatments. Oral HIF-PHI (Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors) are a class of oral medications that target and inhibit prolyl hydroxylase enzymes, which play a role in regulating the hypoxia-inducible factor (HIF) pathway. For instance, in February 2023, GSK plc, a UK-based pharmaceutical company, launched Jesduvroq, a treatment designed to improve red blood cell production and address anemia in adult patients with chronic kidney disease. This innovative anemia drug system features enhanced iron metabolism, improved red blood cell production, and personalized therapies. Jesduvroq is highly effective, boosting red blood cell production and addressing anemia in chronic kidney disease patients by enhancing iron metabolism for better treatment outcomes.
Which leading companies are dominating the anemia drugs market landscape?
Major companies operating in the anemia drugs market are Pfizer Inc., AbbVie Inc., Bayer Aktiengesellschaft, Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Fresenius SE & Co. KGaA, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Biocon Limited, Akebia Therapeutics Inc., Apellis Pharmaceuticals Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Covis Pharma GmbH, AdvaCare Pharma LLC, Regen Biopharma Inc., BioLineRx Ltd., Bluebird Bio Inc.
Which geographic areas are expected to offer the highest growth opportunities in theanemia drugs market?
North America was the largest region in the anemia drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anemia drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Anemia Drugs Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24141&type=smp
Need Customized Data On Anemia Drugs Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24141&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
